Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Galunisertib (Primary) ; Enzalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 06 Jun 2025 Planned primary completion date changed from 1 May 2025 to 1 Dec 2025.
- 21 Oct 2024 Planned End Date changed from 1 Dec 2025 to 1 May 2026.
- 21 Oct 2024 Planned primary completion date changed from 1 Oct 2024 to 1 May 2025.